Synthetic Biologics (SYN) Tops Q2 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
- S&P 500, Nasdaq hit record highs as Treasury yields stall, oil slips
- Oil prices fall nearly 2% as Middle East supply concerns ease
- U.S. 10-year yield climb revives dotcom-era parallels: UBS weighs in
- Goldman flags 2 key market risks if a climb in yields persists
- Shell CEO says Middle East oil flows reach 80% of prewar levels
- HubSpot to cut 7% of workforce in restructuring plan
- Paramount Skydance to close WBD deal, change ticker to SKYD
- Citi cuts investment banking analyst program to two years - Bloomberg
- Emera and Canadian Utilities agree to merge in $72B all-share deal
- Nasdaq notches record high close as investors focus on earnings
Synthetic Biologics Reports Second Quarter 2016 Operational Highlights and Financial Results
August 3, 2016 4:01 PM EDTROCKVILLE, Md., Aug. 3, 2016 /PRNewswire/ --Â Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, today provided an operational update and reported financial results for the three months ended June 30, 2016.
"In the second... More



